Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma
about
Current Trends of Renal Impairment in Multiple MyelomaA phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaSalvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma.Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.Current strategies for treatment of relapsed/refractory multiple myeloma.An update on the use of lenalidomide for the treatment of multiple myeloma.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.Comment on "Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma".RAS mutation status and bortezomib therapy for relapsed multiple myeloma.LncRNA MALAT-1 Elevates HMGB1 to Promote Autophagy Resulting in Inhibition of Tumor Cell Apoptosis in Multiple Myeloma.The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.
P2860
Q26740444-D3EBB4E6-DD7A-4487-8B47-7CC3D288DE11Q33412684-9E7CEB40-DCF5-4E54-B965-E59EAC2F737AQ33414239-E60B10A7-890B-4144-ABAC-D7E518E30D2FQ33437045-1E1F9DEC-B47A-4BB9-AD1C-7D338CE4C93DQ34798095-6BD6BE9B-BDE0-42F4-B23A-B73ACBA78539Q37373159-771D7FA0-EF4D-4045-811D-E94479EEE003Q38182683-3EA6CBDF-C424-4FD5-A543-CED88078A19AQ38545607-A29680A5-C104-47FC-BED7-7D5A264C5565Q38672091-A9D00651-75D2-40C8-ACB8-362613FB577CQ38757067-23CFB309-351F-49C9-9227-CDBF4F37D194Q40047253-FFEA4D6E-00DE-4060-AC64-7F14B524978BQ42046604-C61FB6C0-8CC7-41D3-B475-E4F1D6219BA1Q42943388-4205168D-245D-495E-B216-847718E828D0Q45066307-D4D75910-1054-4E91-8816-DD1A2273D0C8Q48125035-EDD40F6C-A2AF-479D-B3E3-92750E688ADCQ53619518-D668F058-7188-4FD8-98DC-12E8814C7CEA
P2860
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phase II study of bortezomib-d ...... patients with multiple myeloma
@ast
Phase II study of bortezomib-d ...... patients with multiple myeloma
@en
type
label
Phase II study of bortezomib-d ...... patients with multiple myeloma
@ast
Phase II study of bortezomib-d ...... patients with multiple myeloma
@en
prefLabel
Phase II study of bortezomib-d ...... patients with multiple myeloma
@ast
Phase II study of bortezomib-d ...... patients with multiple myeloma
@en
P2093
P2860
P1433
P1476
Phase II study of bortezomib-d ...... patients with multiple myeloma
@en
P2093
Catherine Couturier
Esther Broer
Huw Roddie
Lotfi Benboubker
Marie-Andrée Mazier
Meral Beksac
Nathalie Allietta
Ralf Angermund
P2860
P304
P356
10.3324/HAEMATOL.2013.084376
P577
2013-05-28T00:00:00Z